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A B S T R A C T
Background: Experimental studies in rodents suggest that polybrominated diphenyl ethers (PBDEs) and poly-
and perfluoroalkyl substances (PFAS) may contribute to depressive symptoms. Few studies have examined the
impact of these chemicals on depression in adults.
Objective:
To examine the associations between serum PBDE and PFAS concentrations during pregnancy and repeated
measures of depressive symptoms in women assessed from pregnancy to 8 years postpartum.
Methods:
This study was based on 377 women from the Health Outcomes and Measures of the Environment Study, a
birth cohort in Cincinnati, OH (USA). PBDEs (BDE-28, -47, -99, -100, -153, and ∑PBDEs) and PFAS (per-
fluorooctanoate [PFOA], perfluorooctane sulfonate [PFOS], perfluorohexane sulfonate [PFHxS], per-
fluorononanoate [PFNA]) were quantified in maternal serum at 16 ± 3 weeks gestation. Depressive symptoms
were measured using the Beck Depression Inventory-II (BDI-II) at ~20 weeks gestation and up to seven times
during postpartum visits (4 weeks, 1, 2, 3, 4, 5, and 8 years). We used linear mixed models to estimate covariate-
adjusted associations between chemical concentrations and repeated measures of BDI-II. Multinomial logistic
regression models were used to estimate the relative risk ratios of having a medium or high depression trajec-
tory.
Results:
We found that a 10-fold increase in BDE-28 at 16 ± 3 weeks gestation was associated with significantly
increased BDI-II scores (β = 2.5 points, 95% confidence interval [CI] 0.8, 4.2) from pregnancy to 8 years
postpartum. Significant positive associations were also observed with BDE-47, -100, -153, and ∑PBDEs. A 10-fold
increase in ∑PBDEs was associated with a 4.6-fold increased risk (95% CI 1.8, 11.8) of a high trajectory for BDI-II
compared to a low trajectory. We observed no significant associations between PFAS and BDI-II scores.
Conclusion:
PBDEs during pregnancy were associated with more depressive symptoms among women in this cohort.
https://doi.org/10.1016/j.envint.2020.105694
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The prevalence of clinically significant depression in women, de-
fined as severe symptoms affecting various aspects of daily life that
persists for at least two weeks, ranges from 10 to 23% during pregnancy
and postpartum (Bennett et al., 2004; Ertel et al., 2011; Mayberry et al.,
2007). Women who experience symptoms of depression during this
time may face many issues, including more sexual problems, deficient
social support systems, increased risk of anemia, increased anxiety and
fatigue, loss of sleep, and more harmful health behaviors, including
alcohol and substance abuse (Asselmann et al., 2016a, 2016b; Kang
et al., 2020; Zuckerman et al., 1989). Maternal depression is also as-
sociated with lower maternal functioning. Studies report that mothers
with depression are less sensitive to child cues, provide less positive
stimulation, have more parenting difficulties, and are less adherent to
medical and preventive practices than their non-depressed counterparts
(Coyl et al., 2002; Field, 2002; Leiferman, 2002; McLennan and
Kotelchuck, 2000; Pelaez et al., 2008). Maternal depression has been
documented to adversely affect offspring health, from infancy to ado-
lescence (Campbell et al., 2009; Field et al., 2006; Goodman et al.,
2011; Stewart, 2007). Children of depressed mothers are more likely to
experience general psychopathology, exhibit more internalizing and
externalizing problems, suffer from diminished cognitive functioning,
and display suboptimal physical growth (Ertel et al., 2010; Goodman
et al., 2011; Hay et al., 2008). Maternal depression during childhood is
also associated with poorer academic performance (Murray et al.,
2010). Adverse cognitive and behavioral outcomes in children may
persist even after remission of maternal depression (Moehler et al.,
2006; Murray, 1992; Murray et al., 1996), although some studies sug-
gest psychotherapy and antidepressant treatment can improve out-
comes for both women and their children (Goodman and Garber, 2017).
Studies have found that alleviating maternal depression can improve
children’s mental health as well as reducing internalizing and ex-
ternalizing behavioral problems (Cuijpers et al., 2015; Forman et al.,
2007).
Depression is affected by alterations in the hypothalamic-pituitary-
thyroid axis (Loh et al., 2019). In addition, dopamine dysfunction,
particularly diminished dopaminergic neurotransmission, is involved in
the pathophysiology of depression (Dunlop and Nemeroff, 2007). Re-
ductions in dopamine release and impairments in signal transduction
are potential underlying mechanisms contributing to depressive
symptoms. Polybrominated diphenyl ethers (PBDEs) and poly- and
perfluoroalkyl substances (PFAS) are endocrine disrupting chemicals
that may play a role in the pathomechanism of depression by disrupting
dopamine and thyroid function - similar to that observed for exposure
to polychlorinated biphenyls (PCBs), which are structurally similar to
PBDEs and share physiochemical properties (Gaum et al., 2019).
PBDEs are flame retardants that were used in polyurethane foam for
furniture and carpet padding and in the hard plastic casings in appli-
ances and electronics. Despite the phase out of Penta- and OctaBDE in
2004 and DecaBDE subsequently in 2013 (Linares et al., 2015), BDE-28,
-47, -99, -100, and -153 were still detected in>90% of the general U.S.
population in the National Health and Nutrition Examination Survey
(NHANES) for the years 2005/2006 through 2013/2014 (Sjodin et al.,
2019). Interest in PBDEs as potential chemicals of concern for depres-
sion stem from their similar structure and toxicological properties to
PCBs, which have been documented to interfere with the dopamine
system by disrupting tyrosine hydroxylase activity, disturbing dopa-
mine transport, and affecting dopamine metabolism (Choksi et al.,
1997; Fonnum and Mariussen, 2009; Putschogl et al., 2015; Seegal
et al., 2010). PBDEs have also been reported to disrupt the dopami-
nergic system (Bradner et al., 2013; Slotkin et al., 2013; Wang et al.,
2015). PFAS may play a role in the etiology of neuropsychiatric dis-
orders by altering dopaminergic synapses, disturbing dopaminergic
gene transcription, modifying neuronal activity, and inhibiting gene
and protein expression of dopamine receptors (Hallgren and Viberg,
2016; Patel et al., 2016; Salgado et al., 2016). Both PBDEs and PFAS
have been identified to disrupt thyroid hormones in humans
(Ballesteros et al., 2017; Czerska et al., 2013; Herbstman and Mall,
2014; Kim et al., 2018). PBDEs may disrupt thyroid hormone home-
ostasis via competitive binding to thyroid hormone receptors and
thyroid transport protein transthyretin as well as inducing thyroxine
glucuronidation, thereby increasing thyroxine clearance (Meerts et al.,
2000; Richardson et al., 2008; Zhou et al., 2002). Reductions in thyr-
oxine observed with PFAS exposure may be due to increased metabo-
lism from upregulating hepatic transport proteins, increased glucur-
onidation, upregulated deiodinase enzyme DIO1, and displaced
thyroxine-bound receptors (Chang et al., 2008; Weiss et al., 2009; Yu
et al., 2009; Yu et al., 2011). Hypothyroidism and subclinical hy-
pothyroidism have been associated with depressive symptoms (Hage
and Azar, 2012; Loh et al., 2019).
No study has examined PBDEs or PFAS during pregnancy and ma-
ternal depression. Given the potential for PBDEs and PFAS to contribute
to the pathophysiology of depression based on mechanisms demon-
strated by PCBs as well as the relatively long half-lives of these com-
pounds in the human body, we investigated the relationship between
serum concentrations of PBDEs and PFAS among women in their early
second trimester of pregnancy and depressive symptoms from preg-
nancy to 8 years postpartum. In addition to analysis of outcome at an
individual time point, we examined the trajectories of depressive
symptoms to reflect patterns of symptom change during this period. We
hypothesize that PBDE and PFAS concentrations during pregnancy are
associated with more depressive symptoms in women as well as a tra-
jectory of depression throughout the period.
2. Methods
2.1. Study design and cohort
The Health Outcomes and Measures of the Environment (HOME)
Study is an ongoing prospective pregnancy and birth cohort of mother-
child dyads in the greater Cincinnati area (Braun et al., 2017a). Preg-
nant women were recruited from March 2003 to February 2006 from
nine prenatal clinics if they met the following inclusion criteria: (1)
18 years of age; (2) 16 ± 3 weeks of gestation; (3) residing in housing
constructed before 1978; (4) receiving and planning to continue pre-
natal care and deliver at one of the collaborating obstetric practices; (5)
HIV- status; and (6) not taking any medications related to seizures,
thyroid disorders, or chemotherapy/radiation. Of the 1263 eligible
women identified via clinical records and phone interviews, there were
468 women who enrolled and 390 who subsequently delivered liveborn
singletons. Follow-up visits consisted of home visits, telephone inter-
views, and clinic visits. Participants missing a particular follow-up visit
(e.g., 2 year postpartum) were not excluded from the study and might
complete a subsequent follow-up visit (e.g., 5 years postpartum). The
availability of at least one assessment of depressive symptoms was a
requirement to be included in the present study, as a longitudinal mixed
model was employed. A total of 377 had at least one assessment of
depressive symptoms from baseline to 8 years postpartum and a mea-
surement of either PBDEs or PFAS quantified at enrollment. Of these
women, biomonitoring was completed during pregnancy for the fol-
lowing: 96% (n = 361) for PBDEs, 94% (n = 360) for PFAS, and 90%
(n = 339) for both chemical classes. The study protocol was approved
by the Institutional Review Board (IRB) at the Cincinnati Children’s
Hospital Medical Center (CCHMC). The Centers for Disease Control and
Prevention (CDC) deferred to CCHMC IRB as the IRB of record.
2.2. Concentrations of PBDEs and PFAS
Maternal blood samples were collected at ~16 ± 3 weeks gesta-
tion. Serum was separated and stored at −70 °C until analysis. Details
regarding quality assurance, quantification procedures, and lipid
A.M. Vuong, et al. Environment International 139 (2020) 105694
2
adjustment have been described previously (Vuong et al., 2016).
Briefly, gas chromatography/isotope dilution high-resolution mass
spectrometry was used to quantify PBDE congeners -17, -28, -47, -66,
-85, -99, -100, -153, -154, and -183 (Jones et al., 2012; Sjodin et al.,
2004). For the present study, we focused on PBDE congeners BDE-28,
-47, -99, -100, and -153, as well as their sum (∑PBDEs), which had
detection frequencies> 87% (see Supplemental Table S1). Because
detection frequencies were high and percentages of PBDE measure-
ments below the limit of detection (LOD) were low, we substituted
values< LOD with LOD/√2 as recommended by Hornung and Reed
(1990).
PFAS compounds, including perfluorooctanoate (PFOA), per-
fluorooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), and
perfluorononanoate (PFNA), were measured using on-line solid-phase
extraction coupled to high-performance liquid chromatography-isotope
dilution-tandem mass spectrometry (Kato et al., 2011). For women
without PFAS measurements at 16 ± 3 weeks, we substituted mea-
surements quantified at 26 weeks gestation (n = 35) or at parturition
(n = 17). For those with>1 measurement during pregnancy (n = 70),
an average was used for prenatal PFAS. All PFAS compounds were
detected in all serum samples (see Supplemental Table S1). PBDEs and
PFAS concentrations were log10- and ln-transformed (due to a lower
range of concentrations), respectively, to reduce the influence of out-
liers.
2.3. Maternal depression
Maternal depressive symptoms were measured using the Beck
Depression Inventory-II (BDI-II) at ~20 weeks of gestation and seven
postpartum visits, including 4 weeks, 1, 2, 3, 4, 5, and 8 years (Beck
et al., 1996). For the majority of women, the BDI-II was self-adminis-
tered. In a few cases when literacy was in question, it was administered
orally by a research assistant. All research assistants were trained in
proper administration and scoring of the measure by a developmental
psychologist with over 25 years of experience in test administration,
scoring, and interpretation. The 21-item questionnaire consisted of
areas related to mental and somatic components of depression. Symp-
toms of depression may include feelings of hopelessness or irritability,
and signs of depression may manifest physically, such as feeling fatigue,
experiencing weight loss, or lacking interest in sex. Responses were
rated on a 4-point Likert scale, from 0, “not at all,” to 3, “severely.”
Total scores on the BDI-II ranged from 0 to 63, with scores ≤13 con-
sidered “minimally depressed,” 14–19 considered “mildly depressed,”
20–28 considered “moderately depressed,” and>28 considered “se-
verely depressed.” Because of the low percentages of HOME Study
women who had BDI-II scores considered moderately, severely, or
clinically depressed, we categorized BDI-II scores into> 13 as women
exhibiting “some depressive symptoms,” and ≤13 as women exhibiting
“little to no depressive symptoms” (see Supplemental Table S2). Re-
search coordinators executing the study visits did not have knowledge
of the participants’ previous responses on the measure. They also did
not have information about specific exposures of interest at the time of
the study visit. Protocols for explaining the BDI-II, providing instruc-
tions for its completion, review and tally of total scores according to the
published manual, and delivery of intervention (as needed) were em-
ployed to ensure standardization of the process across all study parti-
cipants.
2.4. Statistical methods
Intraclass correlation coefficients were calculated for BDI-II scores
measured at 8 visits. We used linear mixed models to estimate βs and
95% confidence intervals (CIs) for individual PBDEs, ∑PBDEs, and the
four individual PFAS in relation to repeated measurements of BDI-II
scores assessed from ~20 weeks of gestation to 8 years postpartum. We
only present overall estimates for repeated BDI-II scores rather than
visit-specific estimates because the interaction terms between con-
tinuous measures of our exposure (PBDEs or PFAS) and visit (catego-
rical) were not all statistically significant (see Supplemental Tables S3
and S4). We also examined whether higher concentrations of PBDEs or
PFAS were associated with higher odds of having a score “at risk” of
depression, defined in our study as a BDI-II score> 13, using general-
ized linear models.
We categorized women into three different groups according to
their 9-year longitudinal trajectory of BDI-II score patterns from early
second trimester of pregnancy to 8 years postpartum. The group-based
trajectory modeling (GBTM) was performed using Stata/IC 12.1 pro-
cedure Traj to identify clusters of individuals with similar progressions
of BDI-II scores using a zero-inflated Poisson model with a quadratic
polynomial trajectory function that allows for an inflection point within
the data (Jones and Nagin, 2013; Nagin et al., 2018). GBTM assumes
that the population distribution of BDI-II trajectories arises from a finite
mixture of unknown groups. It does not identify a true number of tra-
jectory groups since there is no true number, but it distinguishes dis-
tinct features of the population with similar trajectories. Using a general
quasi-Newton procedure, GBTM predicts each groups’ trajectory, esti-
mates the probability that an individual is within each group, and as-
signs an individual to the group that they have the highest probability
to be in. Almost half of the women in the HOME Study had a BDI-II
score trajectory that was categorized as low, 40% of women were ca-
tegorized as medium, and about 10% had a high depression trajectory
(Fig. 1). We used multinomial logistic regression models to estimate the
excess relative risk of being in the medium or high BDI-II score tra-
jectory relative to the low trajectory with increasing PBDE or PFAS
concentrations, yielding relative risk ratios (RRRs) and 95% CIs. All
models were adjusted for maternal age, race/ethnicity, household in-
come at enrollment, self-reported marijuana use during pregnancy,
serum cotinine as a measure of tobacco use or secondhand smoke ex-
posure, serum ∑PCBs, maternal IQ, marital status, and parity based on a
review of the literature and bivariate analysis with both exposure and
outcome (p < 0.20).
We conducted a sensitivity analysis using only PFAS concentrations
measured at 16 ± 3 weeks of gestation, regardless of whether the
participant had more than one measurement at multiple time points
(n = 303) to address potential concerns of exposure misclassification
bias. We also performed a number of sensitivity analyses with addi-
tional adjustment for pre-pregnancy body mass index (BMI), blood lead
levels during pregnancy, if women breastfed (yes/no), alcohol con-
sumption (never,< 1/month,> 1/month), and polyunsaturated fatty
acid (PUFA) intake to alleviate concerns of residual confounding out-
side of the covariates included in our final model. PUFA levels were
Fig. 1. Trajectories of BDI-II scores from pregnancy to 8 years postpartum,
HOME Study.
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calculated based on reported total intake of fish consumption (types,
frequency) during pregnancy using data from the USDA National
Nutrient Database. We also adjusted for time varying covariates, in-
cluding household income, marital status, paternal education, per-
ceived social support, and neighborhood quality, to take into account
changes that may have occurred following baseline which may have
resulted in information bias. Social support was categorized into high,
moderate, and low based on participant responses to questions in-
quiring about help received from family and friends living nearby. It
was measured by two questions inquiring about family and friends,
which asked, “How much help would you expect to get from [FAMILY/
FRIENDS] living nearby?” Neighborhood quality was determined based
on two sets of questions. First, regarding the likelihood of participants’
neighbors getting involved in various scenarios involving their chil-
dren, the neighborhood, and the community. The first set of questions
for neighborhood involvement contained five questions asking, “How
likely would your neighbors intervene if…”: (1) “children were skip-
ping school and hanging out on a street corner?”; (2) “if children were
spray-painting graffiti on a local building?”; (3) “if children were
showing disrespect to an adult?”; (4) “a fight broke out in front of their
house?”; and (5) “the fire station closest to their house was threatened
with budget cuts?” Second, participants were asked to agree with
statements inquiring about the willingness of neighbors to help others,
the level of familiarity within the neighborhood, trustworthiness, and
the ability of neighbors to get along. The set of five statements consisted
of the following: (1) “People around my home are willing to help their
neighbors”; (2) “I live in a close-knit neighborhood”; (3) “People in my
neighborhood can be trusted”; (4) People in my neighborhood generally
don’t get along with each other”; and (5) “People in my neighborhood
do not share the same values.”
3. Results
3.1. Study participants
The mean age at baseline was 29.4 years, with 61.8% of the women
identifying as non-Hispanic white and 50% having a Bachelor’s degree
or higher. Approximately 60% had an annual household income at
baseline ≥$40,000, and 79% were married or living with a partner.
Concentrations of ∑PBDEs during pregnancy were lower among older
women, non-Hispanic whites, those with higher education and income,
and among women who were married/living with a partner (Table 1).
PFOA and PFOS concentrations were higher among non-Hispanic
whites and among women who were nulliparous. Lower BDI-II scores
during pregnancy and at 8 years postpartum were observed among
women who were non-Hispanic white, married or living with a partner,
more educated, had a higher household income, and non-marijuana
users.
3.2. Longitudinal trends of maternal depression
The intraclass correlation coefficient for BDI-II scores was 0.58,
indicating good reproducibility between BDI-II assessments across time.
BDI-II scores were highest during pregnancy, with a mean of
10.0 ± 7.0 (see Supplemental Table S2). Scores declined after de-
livery, with the lowest mean of 5.5 ± 6.0 at 5 years postpartum.
However, at 8 years postpartum, the mean of BDI-II scores increased to
7.4 ± 7.3. The percentage of women exhibiting some depressive
symptoms (BDI-II scores> 13) was highest during pregnancy (22.3%)
followed by 8 years postpartum (18.4%). Moderately and severely de-
pressed women, defined as individuals with a BDI-II score ≥20, were
observed in less than 10% of the HOME Study women at every time
point.
3.3. Serum PBDEs and PFAS during pregnancy and maternal depression
BDI-II scores were positively associated with concentrations of
PBDEs during pregnancy after covariate adjustment (Fig. 2). Aside from
BDE-99, all PBDE congeners and ∑PBDEs were significantly positively
associated with BDI-II scores. A 10-fold increase in BDE-28 concentra-
tions at 16 ± 3 weeks gestation was associated with a 2.5-point in-
crease (95% CI 0.8, 4.2) in BDI-II scores from pregnancy to 8 years
postpartum. We observed similar statistically significant positive asso-
ciations between BDI-II and BDE-47, -100, -153, and ∑PBDEs. Higher
odds of having a BDI-II score> 13 from pregnancy to 8 years post-
partum was observed among women with higher concentrations of
BDE-28, -47, -100, -153, and ∑PBDEs (see Supplemental Table S5). A
10-fold increase in ∑PBDEs during the early second trimester of preg-
nancy was significantly associated with approximately a 2-fold risk
(95% CI 1.4, 4.2) of having a BDI-II score that would indicate potential
depressive symptoms from pregnancy to 8 years postpartum.
When we examined trajectories of maternal depressive symptoms,
we observed significantly higher risk of having a high BDI-II score
trajectory with 10-fold increases in several PBDE congeners and
∑PBDEs compared to a low BDI-II score trajectory (Table 2). Both BDE-
47 and BDE-99 had statistically significant RRRs for medium and high
BDI-II score trajectories. A 10-fold increase in ∑PBDEs was associated
with a 4.6 increase in risk (95% CI 1.8, 11.8) of having a high BDI-II
trajectory compared to a low trajectory.
Serum concentrations of PFAS during pregnancy were not asso-
ciated with BDI-II scores measured from pregnancy to 8 years post-
partum (Fig. 2). In addition, no relationship was noted between PFAS
and higher odds of having an “at risk” BDI-II score (see Supplemental
Table S5).
3.4. Sensitivity analyses
Examination of PFAS measured only at 16 weeks gestation did not
yield findings that were discordant from our original results
(Supplemental Table S6). Additional adjustment for perceived social
support and neighborhood quality, pre-pregnancy BMI, blood lead le-
vels during pregnancy, breastfeeding, alcohol consumption, and PUFA
levels did not change our results (see Supplemental Table S7). After
including paternal education at baseline as well as a time-varying pa-
ternal education variable in two separate sensitivity analyses, we no
longer observed a significant association between BDE-100 and BDI-II
scores (see Supplemental Table S8). However, all other significant po-
sitive associations between BDE-28, -47, -153, and ∑PBDEs remained.
4. Discussion
In the HOME Study, we found that PBDE concentrations during
pregnancy were significantly associated with higher depressive symp-
toms in women. Several PBDE congeners as well as ∑PBDEs had sta-
tistically significant positive associations with BDI-II scores, suggesting
that PBDEs may play a role in the pathogenesis of depression. In con-
trast, there was no evidence to indicate that serum concentrations of
PFAS during pregnancy are related to maternal depressive symptoms.
Some studies have examined PBDEs and internalizing behaviors in
children. While most reported null associations (Braun et al., 2017b;
Chen et al., 2014; Gump et al., 2014; Hoffman et al., 2012), higher
PBDE concentrations have been associated with improvement in in-
ternalizing behaviors in some studies (Adgent et al., 2014; Roze et al.,
2009) and worsening of internalizing behaviors in others (Lipscomb
et al., 2017). Because no studies have examined PBDEs and depression
in adults, studies investigating PCBs and depression in adults may serve
as a comparison as PBDEs are structurally similar and have analogous
toxicological properties (Costa et al., 2014). In a longitudinal study,
individuals with a higher PCB burden had increased risk of developing
depressive symptoms (Gaum et al., 2014). PCBs were also positively
A.M. Vuong, et al. Environment International 139 (2020) 105694
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associated with depressive symptoms among occupationally exposed
workers and their relatives in the German Health Effects in high Level
exposure to PCB (HELPcB) surveillance program (Gaum et al., 2017).
The authors noted that depressive symptoms might be mediated by
Table 1
Serum concentrations of ∑PBDEs (ng/g lipid), PFOA and PFOS (both in ng/mL), and BDI-II scores by maternal characteristics, HOME Study.a
∑PBDEs PFOA PFOS BDI-II: Baseline BDI-II: 8 years
n GM ± GSD n GM ± GSD n GM ± GSD n GM ± GSD n GM ± GSD
Age, years
< 25 74 47.5 ± 2.2* 87 5.5 ± 1.8 87 12.2 ± 1.9 87 13.7 ± 8.4* 59 8.9 ± 7.5
25–34 179 39.6 ± 2.7 210 5.1 ± 1.7 210 12.7 ± 1.6 226 8.8 ± 6.1 131 6.8 ± 7.1
≥35 47 29.4 ± 2.5 57 5.9 ± 1.8 57 14.1 ± 1.6 60 8.8 ± 6.4 32 7.3 ± 7.5
Race/ethnicity
Non-Hispanic White 183 32.5 ± 2.5* 216 5.6 ± 1.7* 216 13.9 ± 1.6* 231 7.9 ± 5.6* 135 6.0 ± 6.6*
Non-Hispanic Black and Others 118 53.1 ± 2.6 139 4.8 ± 1.7 139 11.1 ± 1.8 142 13.2 ± 7.9 88 9.6 ± 7.7
Education
High school or less 83 56.4 ± 2.4* 94 5.2 ± 1.8 94 11.3 ± 1.9 97 14.5 ± 9.1* 61 9.8 ± 7.5*
Some college/2 yr degree 72 40.5 ± 2.3 86 5.4 ± 1.7 86 12.9 ± 1.8 88 11.1 ± 6.3 57 9.2 ± 7.9
Bachelor’s 88 34.1 ± 2.5 105 5.5 ± 1.8 105 13.4 ± 1.5 109 7.4 ± 4.3 65 5.2 ± 6.7
Graduate or professional 57 28.7 ± 3.1 69 5.1 ± 1.7 69 13.7 ± 1.6 79 6.7 ± 4.2 39 5.0 ± 4.7
Family Income
<$40,000 123 49.3 ± 2.6* 145 4.9 ± 1.8 145 11.2 ± 1.9* 147 13.4 ± 8.5* 92 9.7 ± 7.6*
$40,000–$79,999 97 37.8 ± 2.6 113 5.5 ± 1.7 113 13.3 ± 1.6 123 8.3 ± 5.0 73 5.4 ± 6.9
≥$80,000 81 29.5 ± 2.4 97 5.7 ± 1.8 97 14.7 ± 1.6 103 7.1 ± 4.4 58 6.3 ± 6.1
Marijuana Use
Yes 277 38.5 ± 2.6 329 5.3 ± 1.7 329 13.1 ± 1.7* 344 9.4 ± 6.6* 207 7.0 ± 7.0*
No 23 54.5 ± 2.2 25 5.0 ± 1.8 25 9.0 ± 1.9 29 16.4 ± 8.7 15 13.7 ± 8.6
Parity
Nulliparous 132 35.2 ± 2.6 153 6.5 ± 1.7* 153 14.7 ± 1.7* 166 9.2 ± 5.8 103 6.7 ± 7.2*
Primiparous 90 41.6 ± 2.4 110 4.4 ± 1.6 110 11.9 ± 1.7 115 10.0 ± 8.5 65 6.3 ± 5.7
Multiparous 76 44.4 ± 2.7 89 4.7 ± 1.7 89 10.9 ± 1.6 90 11.3 ± 6.9 54 10.1 ± 8.4
Marital status
Married/living with partner 236 35.7 ± 2.7* 278 5.3 ± 1.8 278 13.0 ± 1.7 296 8.9 ± 6.5* 165 6.4 ± 6.8*
Not married, living alone 64 57.6 ± 2.1 76 5.3 ± 1.6 76 11.9 ± 1.8 77 13.9 ± 7.8 57 10.3 ± 7.9
Child Sex
Male 138 34.8 ± 2.5* 166 5.2 ± 1.7 166 12.6 ± 1.7 172 9.0 ± 6.4* 99 6.8 ± 6.1
Female 162 44.1 ± 2.7 188 5.4 ± 1.7 188 12.9 ± 1.8 201 10.8 ± 7.5 123 8.0 ± 8.0
Breastfed current child
No 53 46.3 ± 2.2 66 5.5 ± 1.6 66 12.2 ± 1.6 67 12.1 ± 7.9* 45 7.5 ± 6.6
Yes 236 38.0 ± 2.6 277 5.3 ± 1.8 277 13.1 ± 1.7 295 9.3 ± 6.6 176 7.3 ± 7.3
Abbreviations: GM, geometric mean; GSD, geometric standard deviation; SD, standard deviation.
p < 0.05 for two-sided p values using ANOVA.
a Frequencies may not add to the total number of participants because of missing values.
Fig. 2. Estimated score differences and 95% confidence intervals in BDI-II
scores from the early second trimester of pregnancy to 8 years postpartum by a
10-fold increase in serum PBDE concentrations (ng/g lipid) or 1-ln unit increase
in serum PFAS concentrations (ng/mL) during pregnancy, HOME Study.
Adjusted by age, race/ethnicity, household income, maternal marijuana use,
serum cotinine and ∑PCBs, IQ, marital status, and parity.
Table 2
Relative risk ratios (RRRs) and 95% confidence intervals of having a medium or
high BDI-II score trajectory by a 10-fold increase in serum PBDE concentrations




n RRR (95% CI) RRR (95% CI) RRR (95% CI)
PBDEs
BDE-28 276 Referent 1.9 (0.9, 4.0) 6.1 (2.2, 17.1)
BDE-47 312 Referent 1.8 (1.0, 3.3) 5.5 (2.3, 13.1)
BDE-99 312 Referent 1.9 (1.1, 3.4) 4.5 (2.0, 10.1)
BDE-100 312 Referent 1.5 (0.9, 2.6) 3.9 (1.7, 8.9)
BDE-153 311 Referent 1.2 (0.7, 2.0) 1.9 (0.9, 4.1)
∑PBDEs 275 Referent 1.6 (0.9, 3.1) 4.6 (1.8, 11.8)
PFAS
PFOA 300 Referent 1.3 (0.8, 2.0) 0.9 (0.5, 1.9)
PFOS 300 Referent 0.9 (0.6, 1.5) 0.6 (0.3, 1.2)
PFHxS 300 Referent 1.0 (0.7, 1.3) 0.6 (0.4, 1.0)
PFNA 300 Referent 0.8 (0.4, 1.5) 0.7 (0.3, 1.8)
aAdjusted by age, race/ethnicity, household income, maternal marijuana use,
serum cotinine and ∑PCBs, IQ, marital status, and parity.
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altered dopamine metabolism, specifically reporting that there was
significant mediation for lower-chlorinated, higher-chlorinated, and
dioxin-like PCBs. Among older residents residing along the upper con-
taminated portions of the Hudson River in New York, Fitzgerald et al.,
(2008) reported significantly higher BDI-II scores of ~19% with an
increase in serum PCBs from 250 to 500 ppb. In contrast, some studies
have observed null associations between PCBs and adult depression
(Kilburn et al., 1989; Lin et al., 2008; Peper et al., 2005; Seegal et al.,
2013). To our knowledge, only one study has examined PFAS and adult
depression. In contrast with our study, Berk et al. (2014) found that
several PFAS were inversely associated with depression prevalence,
using the NHANES data from 2005 to 2010. Divergent findings may be
related to differences in study design, depression assessment tools,
sample characteristics, and PFAS concentrations.
Our finding that PBDEs are associated with higher depressive
symptoms in women have several possible explanations. First, animal
studies have consistently reported that PBDEs reduce blood levels of
thyroid hormones (Darnerud, 2008), suggesting a hypothyroxinemic or
hypothyroid effect. Overt and subclinical hypothyroidism have been
linked to an increased risk of depression in humans (Constant et al.,
2006; Larisch et al., 2004; Loh et al., 2019). In a pooled analysis of over
12,000 individuals, those with subclinical hypothyroidism had 2-fold
greater risk for depression compared to euthyroid controls (Loh et al.,
2019). PBDEs’ role and impact in the disruption of the hypothalamic-
pituitary-thyroid axis in humans is described in the medical literature
(Albert et al., 2018; Byrne et al., 2018; Chen et al., 2018; Czerska et al.,
2013).
Second, PBDEs can disrupt the dopaminergic system, which plays a
major role in depression. Dopamine is involved in the regulation of
several prominent features of depression, including motivation, psy-
chomotor speed, concentration, and the ability to experience pleasure
(Dunlop and Nemeroff, 2007). Impaired function of the mesolimbic
dopamine system has been reported in rodent models of depression,
suggesting that there is diminished dopamine release and lower dopa-
mine receptor binding (Neill et al., 2002; Papp et al., 1994; Salamone
et al., 1999). DE-71 significantly reduces striatal dopamine, dopamine
handling, and dopamine transporters in vivo, demonstrating that PBDEs
disrupt the nigrostriatal dopamine system (Bradner et al., 2013), which
is involved in motivated behaviors (Smillie and Wacker, 2014). BDE-99
also suppresses neurodifferentiation into dopamine phenotypes in PC12
cells (Slotkin et al., 2013). In zebrafish larvae, PBDE exposure reduced
whole-body dopamine, its metabolite, and dopamine transporter pro-
tein, indicating dopamine synthesis and transport dysregulation (Wang
et al., 2015).
Third, the biological mechanism of action for PBDEs and depression
may involve affecting neuroplasticity, whose functional aspects include
long-term potentiation and depression (Wang et al., 1997). BDE-99
exposure altered levels of key proteins involved in synaptic plasticity,
including Gap-43/neuromodulin and stathmin, in the striatum region of
the mouse brain (Alm et al., 2006). While we did not observe a sig-
nificant linear association between BDE-99 and BDI-II scores, there was
a statistically significant positive association with moderate and high
score trajectories. PBDEs also disrupt Ca2+ signaling, because they are
potent modulators of ryanodine receptors, which play a role in neuro-
transmission and synaptic plasticity (Kim et al., 2011). Because PBDE
exposure can be reduced, it can be considered a modifiable risk factor
for depression during and after pregnancy. While PBDEs are ubiquitous,
exposure can be limited with behavior modification, including re-
placement of PBDE-laden products, regularly vacuuming with a HEPA
filtered vacuum, and frequent handwashing.
One strength of our study is that we used data from the HOME
Study, an ongoing prospective, birth cohort that is rich with covariate
information. This allowed us to adjust for important confounders, in-
cluding socioeconomic factors, marital status, and parity. We were also
able to adjust for PUFA intake in sensitivity analyses as fish consump-
tion has been reported to protect against perinatal depression
(Hamazaki et al., 2018; Lin et al., 2017). We additionally adjusted for
perceived social support from family and friends, paternal education,
and alcohol consumption. A second strength of this study is that we
took into account co-exposures to tobacco smoke and PCBs. PCBs and
PBDEs potentially share similar pathological mechanisms for depres-
sion, because of their structural similarities. A third strength is that we
had up to 8 repeated measures of BDI-II from pregnancy to 8 years
postpartum. Using linear mixed models increased our power to detect
associations between serum PBDEs and PFAS and changes in BDI-II
scores, and we were able to examine trajectories of maternal depres-
sion. Further, yearly time intervals may reduce a possible bias due to
childrearing responsibilities as well as seasonal influences on depressive
symptoms. Last, we utilized BDI-II to assess depressive symptoms in the
HOME Study women. This instrument has been extensively validated
and is reliable, performing well in diverse cohorts and ethnic groups
(Beck et al., 1996; Dadfar and Kalibatseva, 2016; Gregory, 2007; Lee
et al., 2017; Wiebe and Penley, 2005).
This study has some limitations. First, while we adjusted for parity,
we did not have information on subsequent births that may have oc-
curred after the index pregnancy. Maternal depression is associated
with interpregnancy intervals< 24 months (Gurel and Gurel, 2000;
Patchen and Lanzi, 2013). According to the U.S. Department of Health
and Human Services, a third of all pregnancies in the USA from 2006 to
2010 occurred less than 18 months after the prior live birth (2010).
Therefore, it is likely that a portion of HOME Study women may have
had a subsequent birth within 2 years after the index pregnancy, which
may have contributed to depressive symptoms. However, Schetter
et al., (2016) noted that most women (75%) had interpersonal stability
in their depressive symptoms from one postpartum period to the next.
We also did not take into account maternal stress, history of depression,
and antidepressant use. Since history of depression is a major risk factor
for perinatal depression, lack of adjustment could have inflated the
point estimates. For instance, if women who reported perinatal de-
pressive symptoms had a history of depression prior to conception, then
the associations observed between PBDEs during pregnancy and peri-
natal depressive symptoms may not reflect a true relationship as de-
pression was already present prior to PBDE measurement. Further,
without history of depression, it is unclear whether outcome may have
influenced exposure concentrations. Women experiencing depression
prior to pregnancy may engage in less cleaning and hygiene behaviors,
which could have influenced their concentrations of PBDEs as one of
the major routes of exposure is through ingestion and dermal absorp-
tion of house dust. Lack of antidepressant use may have biased the
estimates toward the null. If HOME Study women were taking anti-
depressants then this would lower the depressive symptoms reported by
the participants. In addition, because few HOME Study women had
moderate or severe depression, we could not determine the potential
impact of PBDE or PFAS exposures on severe depressive phenotypes.
Third, we utilized BDI-II to assess depressive symptoms among HOME
Study women, which may have resulted in an overestimation of severity
as it includes somatic items as a measure of depression. The perinatal
period involves physiological and psychosocial changes that may
manifest as somatic symptoms (e.g., changes in appetite, sleep, energy,
mood, sexual interest, etc.) normally characteristic of depression, but
are normal among women adjusting to pregnancy and infant care
(O'Hara and Wisner, 2014; Stewart, 2005). Therefore, including so-
matic items to assess perinatal depression may overstate the level of
depression severity (Pereira et al., 2014) and could have biased esti-
mates away from the null. However, since we only found statistically
significant associations between PBDE concentrations and maternal
depression and not with PFAS concentrations, the identified association
may be reflective of a true relationship. Fourth, selection bias may also
be a concern. However, women included in this analysis comprised of
~97% of the 390 women who delivered singletons. Thus, there was
very little attrition pertaining to the present study. We additionally
utilized an average of PFAS concentrations for 70 women who had>1
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measurement during pregnancy. However, sensitivity analyses ex-
amining only PFAS concentrations at 16 ± 3 weeks gestation were
concordant with our study’s conclusions. Last, the HOME Study is based
on only one study site, which affects our finding’s generalizability, and
we were limited by a modest sample size.
Serum PBDE concentrations during pregnancy were associated with
higher depressive symptom scores in an 8-year follow-up of women. In
contrast, we found no evidence that PFAS are involved in the devel-
opment of maternal depressive symptoms to support our hypothesis.
Additional research is necessary to confirm our findings on PBDE ex-
posure and better understand whether the associations persist over time
and whether they are present in other study populations. Future re-
search should consider important factors that were not taken into ac-
count in the present study with regard to the association between
PBDEs and PFAS during pregnancy and maternal depression, including
history of depression as well as antidepressant usage. Measures of PBDE
and PFAS concentrations postpartum should also be considered to
identify susceptible windows of exposure to these endocrine disruptors
in the pathophysiology of depression.
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